Patient Stratification for Serum LDH Levels Reveals Distinct CLA+ T-Cell Cytokine Secretion in Response to HDM, Clinical Features and Allergic Comorbidities
Authors:
- Irene García-JiménezIGIrene García-Jiménez
- Ignasi Figueras-NartIFIgnasi Figueras-Nart
- Lídia Sans-De San NicolásLNLídia Sans-De San Nicolás
- Laia Curto-BarredoLCLaia Curto-Barredo
- Marta Bertolín-ColillaMBMarta Bertolín-Colilla
- Montserrat Bonfill-OrtíMBMontserrat Bonfill-Ortí
- Sandra Díez-RibasSDSandra Díez-Ribas
- Alex Llobet-Del PinoAPAlex Llobet-Del Pino
- Antonio Guilabert-VidalAGAntonio Guilabert-Vidal
- Anna RyzhkovaARAnna Ryzhkova
- Marta FerranMFMarta Ferran
- Ramon M. PujolRPRamon M. Pujol
Open Access
- 13 August 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (16) , 7821
Abstract
Lactate dehydrogenase (LDH) is a serum biomarker well known to correlate with disease severity in atopic dermatitis (AD). The aim of this study was to explore the cutaneous immune responses and the clinical profile of AD patients in relation to serum LDH levels. To this end, 47 untreated, adult patients with moderate-to-severe AD were stratified by median levels of serum LDH. Circulating memory T-cell responses to house dust mite (HDM) extract, in the presence of autologous lesional epidermal cells, were compared between AD subgroups. The LDHhigh group exhibited significantly higher IL-13, IL-5 and IL-9 in vitro responses confined to the cutaneous lymphocyte-associated antigen (CLA)+ subset compared to LDHlow patients. Clinically, LDHhigh patients were younger and exhibited more severe disease, elevated eosinophil counts in their blood, increased total and specific IgE levels in their plasma, and a higher prevalence of allergic rhinitis. Our data suggests that high LDH levels identify a subgroup of AD patients with a specific immune and clinical profile, and highlight the potential of LDH as a clinical parameter that may enable patient stratification for treatment selection.Keywords
Funding Information
- FIS/ISCIII (Ministerio de Economía y Competitividad e Instituto de Salud Carlos III) (PI21/01179, PI21/00335, PREDOCS-UB 2020, 2021 SGR 01433, FI-SDUR 2020)
- Fondo Europeo de Desarrollo Regional (FEDER) (PI21/01179, PI21/00335, PREDOCS-UB 2020, 2021 SGR 01433, FI-SDUR 2020)
- Universitat de Barcelona (PI21/01179, PI21/00335, PREDOCS-UB 2020, 2021 SGR 01433, FI-SDUR 2020)
- Agency for Management of University and Research Grants of the Generalitat de Catalunya (PI21/01179, PI21/00335, PREDOCS-UB 2020, 2021 SGR 01433, FI-SDUR 2020)
This publication has 47 references indexed in Scilit:
- Neuroimmune communication regulating pruritus in atopic dermatitisJournal of Allergy and Clinical Immunology, 2022
- Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter studyArchives of Dermatological Research, 2021
- Biomarkers in atopic dermatitis—a review on behalf of the International Eczema CouncilJournal of Allergy and Clinical Immunology, 2021
- Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkersJournal of Allergy and Clinical Immunology, 2021
- Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and EndotypeJournal of Investigative Dermatology, 2018
- Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trialJournal of the American Academy of Dermatology, 2018
- Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell populationJournal of Allergy and Clinical Immunology, 2015
- Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitisArchives of Dermatological Research, 2011
- IL-31 is associated with cutaneous lymphocyte antigen–positive skin homing T cells in patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 2006
- Interleukin‐9 potentiates the interleukin‐4‐induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytesEuropean Journal of Immunology, 1993